What is vTv Therapeutics Inc.'s (VTVT) StockRank?

MoatMap's StockRank for vTv Therapeutics Inc. (VTVT) is 41/100, with a Hold signal. This is a composite score combining Quality (48), Value (31), and Momentum (53) factor ranks across MoatMap's 20,000+ stock universe.

Does vTv Therapeutics Inc. have an economic moat?

vTv Therapeutics Inc. (VTVT) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is vTv Therapeutics Inc. a buy, hold, or sell?

MoatMap's current signal for vTv Therapeutics Inc. (VTVT) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is vTv Therapeutics Inc. in?

vTv Therapeutics Inc. (VTVT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VTVT

HOLDREMOVE

vTv Therapeutics Inc. · Healthcare · United States · $132M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-1.5%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

vTv Therapeutics is a micro-cap clinical-stage biotech company with highly binary outcomes. It lacks the structural moat, cash flows, and macro tailwinds required for our concentrated portfolio.

COMPANY DESCRIPTION

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates for challenging metabolic and inflammatory diseases. The company leverages its proprietary drug discovery platform to target underlying disease mechanisms, advancing a pipeline of potential therapies through clinical trials. Its competitive position relies on its ability to successfully navigate the complex drug development process and bring innovative treatments to market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	2.0M	0	1.0M	0	-29.0%
EPS	-10.40	-9.71	-3.20	-3.20	—
Shares	2.0M	2.1M	2.6M	3.9M	+93.3%
Debt	0.7M	0.5M	0.2M	0	-51.4%
Equity	-10.7M	-24.7M	12.2M	64.4M	428.2%
Op CF	-16.0M	-19.1M	-25.3M	-25.3M	—
Inv CF	-21,000	4.4M	0	0	—
Fin CF	14.8M	12.0M	52.6M	77.4M	—

PRICE (1Y)+11.3%

SMA 50SMA 200

$35.74

RSI (14)

59.1

52W High

$44.00

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-37.3%18.5

ROE

-1.5%43.0

GP/Assets

14.3%33.8

Op. Margin

63.1%99.2

FCF/Assets

5.9%74.2

Piotroski

324.1

Int. Cover

-50.0x6.0

D/E Ratio

—N/A

Current Ratio

14.36x92.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-111.0x25.0

P/FCF

25.1x46.5

P/B

6.6x19.6

P/S

3.6x50.3

Div Yield

—N/A

Momentum

52W High %

81%73.2

RS 6M

-9%66.9

SMA 50/200

1.07x77.2

EPS Rev 4W

0.0%49.2

EPS Rev 12W

-4.5%24.3

EPS Improve

-399%1.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$132M

P/E (Forward)

-8.8x

Gross Margin

34.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VTVT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
VTVT	vTv Therapeutics Inc.(you)	$132M	41	HOLD
AGEN	Agenus Inc.	$126M	40	HOLD
EQ	Equillium, Inc.	$185M	41	HOLD
DTIL	Precision BioSciences, Inc.	$179M	43	HOLD
NKTX	Nkarta, Inc.	$205M	42	HOLD
UNCY	Unicycive Therapeutics, Inc.	$210M	39	HOLD
IMUX	Immunic, Inc.	$199M	48	HOLD
KPTI	Karyopharm Therapeutics Inc.	$202M	34	SELL
ANTX	AN2 Therapeutics, Inc.	$191M	33	SELL
NRXP	NRx Pharmaceuticals, Inc.	$170M	30	SELL

Peer medians: ROE -23.7% · P/E 25.2x · Gross margin 44.3%

vTv Therapeutics Inc. (VTVT) — Stock Score Summary

vTv Therapeutics Inc. (VTVT) has a MoatMap StockRank of 41/100 based on Quality (48/100), Value (31/100), and Momentum (53/100) factor scores. The current signal is HOLD. vTv Therapeutics is a micro-cap clinical-stage biotech company with highly binary outcomes. It lacks the structural moat, cash flows, and macro tailwinds required for our concentrated portfolio.

Key Financial Metrics

Price	$35.74
Market Cap	$132M
P/E (Forward)	-8.76
Price/Book	6.57
Return on Equity	-1.5%
Return on Invested Capital	-37.3%
Gross Margin	34.8%
Operating Margin	63.1%
Free Cash Flow	$5M

vTv Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is vTv Therapeutics Inc.’s (VTVT) StockRank?: MoatMap’s StockRank for vTv Therapeutics Inc. (VTVT) is 41/100, with a Hold signal. It is a composite of Quality (48), Value (31), and Momentum (53) factor ranks across MoatMap’s 20,000+ stock universe.
Does vTv Therapeutics Inc. have an economic moat?: vTv Therapeutics Inc. (VTVT) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is vTv Therapeutics Inc. a buy, hold, or sell?: MoatMap’s current signal for vTv Therapeutics Inc. (VTVT) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is vTv Therapeutics Inc. in?: vTv Therapeutics Inc. (VTVT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).